Edition:
United States

Aegerion Pharmaceuticals Inc (AEGR.O)

AEGR.O on Nasdaq

2.75USD
27 Sep 2016
Change (% chg)

-- (--)
Prev Close
$2.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
641,008
52-wk High
$16.63
52-wk Low
$1.23

Latest Key Developments (Source: Significant Developments)

Aegerion Pharmaceuticals announces Q2 2016 financial results
Tuesday, 9 Aug 2016 04:11pm EDT 

Aegerion Pharmaceuticals Inc : Aegerion Pharmaceuticals announces second quarter 2016 financial results . Q2 non-GAAP loss per share $0.72 . Q2 GAAP loss per share $1.59 . Recorded total net product sales of $44.5 million in Q2 of 2016 . Continues to anticipate marketing approval for lomitapide in Japan by year-end 2016 .Recently executed a reduction in workforce of approximately 13% and announced its intention to withdraw lomitapide from eu.  Full Article

Aegerion pharmaceuticals, Qlt Inc agree to strategic merger
Wednesday, 15 Jun 2016 06:55am EDT 

Aegerion Pharmaceuticals Inc : Aegerion Pharmaceuticals and QLT Inc. agree to strategic merger . Each outstanding share of Aegerion common stock will be exchanged for 1.0256 shares of QLT common stock . Broad-based investor syndicate to vote in favor of merger and provide concurrent financing of approximately $22 million . QLT plans to change its name upon closing of proposed transaction to Novelion Therapeutics Inc . QLT's common shares will trade on Nasdaq global select market and Toronto stock exchange . Assuming completion of proposed merger by end of Q3 of 2016, Novelion is expected to have an unrestricted cash balance of over $100 million . Proposed transaction has been approved by boards of directors of both companies . Aegerion's CEO, Mary Szela, will serve as CEO of Novelion following close of transaction . $22 million investment would be funded immediately prior to deal close, expected to provide Novelion with additional capital to support operations . As result of structure of deal, repayment obligation with respect to co's outstanding convertible notes will not be triggered . Broad-based investor syndicate to buy about $22 million in shares of QLT common stock for $1.76 per share . After completion, QLT shareholders to own about 67 percent, current Aegerion shareholders to own about 33 percent Novelion's shares . Following close of transaction, Novelion is expected to have its principal headquarters in Vancouver, British Columbia.  Full Article

Aegerion Pharmaceuticals reports Q1 non-gaap loss of $1.72 per share
Monday, 16 May 2016 04:05pm EDT 

Aegerion Pharmaceuticals Inc Says Continues To Expect Full : Aegerion Pharmaceuticals Inc says recorded total net product sales of $35.7 million in q1 of 2016 . Aegerion Pharmaceuticals Inc says expect research and development expenses to decrease slightly in 2016 as compared to 2015 . Year 2016 global net product sales to be between $130 million and $150 million . Year 2016 global net product sales of juxtapid to be between $90 million and $100 million . Year 2016 global net product sales of myalept to be between $40 million and $50 million . Aegerion Pharmaceuticals Inc says s currently analyzing all areas of investment and resources with a goal of reducing 2016 expenses . Aegerion Pharmaceuticals announces first quarter 2016 financial results . Q1 gaap loss per share $2.22 . Q1 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S .Q1 non-gaap loss per share $1.72.  Full Article

Aegerion reaches preliminary agreements with DOJ and SEC on ongoing probe
Thursday, 12 May 2016 08:30am EDT 

Aegerion Pharmaceuticals Inc : Aegerion Pharmaceuticals announces preliminary agreements in principle with DOJ and SEC related to ongoing investigations . Consolidated monetary package includes payments to DOJ and SEC totaling about $40 million . Company would plead guilty to two misdemeanor misbranding violations of food, drug and cosmetic act . One count would be based on company's alleged marketing of juxtapid with inadequate directions for use . Agreements in principle with DOJ, SEC regarding ongoing investigations into co's sales activities related to juxtapid . Company has increased its existing reserve related to investigations by approximately $28 million . Second count would involve an alleged failure to comply with a requirement of juxtapid risk evaluation and mitigation strategies program . Increased reserve of approximately $28 million was recorded in Q1 of 2016 . Would separately enter 5-year deferred prosecution agreement with regard to charges that co violated health insurance portability,accountability act . Preliminary agreement with DOJ requires co to enter civil settlement agreement with DOJ to resolve alleged violations of false claims act . Would enter into non-monetary consent decree with FDA prohibiting future violations of law.  Full Article

Aegerion Pharmaceuticals files for non-timely 10-Q
Wednesday, 11 May 2016 06:27pm EDT 

Aegerion Pharmaceuticals : Aegerion Pharmaceuticals Inc says files for non-timely 10-Q .Intends to file the form 10-Q no later than May 16, 2016.  Full Article

Aegerion Pharmaceuticals Inc cuts 25 pct of global workforce
Thursday, 11 Feb 2016 07:01am EST 

Aegerion Pharmaceuticals Inc:Announces reduction in workforce as part of cost reduction plan.Says announced that it is reducing approximately 25 percent of its global workforce.Says reduction in force includes positions in all major departments.Expects to complete the reduction in force by the end of the second quarter of 2016.  Full Article

Aegerion Pharmaceuticals Inc updates FY 2015 total net product sales guidance
Monday, 11 Jan 2016 08:00am EST 

Aegerion Pharmaceuticals Inc:Expects FY 2015 total net product sales expected to be between $236.5 mln and $239.5 mln.  Full Article

Aegerion Pharmaceuticals Inc appoints Mary Szela as Chief Executive Officer
Thursday, 7 Jan 2016 09:24am EST 

Aegerion Pharmaceuticals Inc:Mary Szela has been appointed as chief executive officer and a member of Aegerion's Board of Directors.Szela succeeds Sandford "Sandy" Smith.  Full Article

Aegerion Pharmaceuticals, Inc raises FY 2015 global net product sales guidance
Monday, 9 Nov 2015 04:05pm EST 

Aegerion Pharmaceuticals, Inc:Expects total FY 2015 global net product sales to be between $230 million and $245 million, revised from the prior range of between $205 million and $235 million.FY 2015 revenue of $239 million - Thomson Reuters I/B/E/S.  Full Article

Aegerion Pharmaceuticals, Inc reaffirms FY 2015 net product sales guidance
Wednesday, 5 Aug 2015 04:10pm EDT 

Aegerion Pharmaceuticals, Inc:Reiterates FY 2015 total net product sales guidance of between $205 and $235 million.  Full Article